Monitor outcomes to ensure long-term PRRS control success. Track diagnostic results and pig performance data across sow, grow-finish, and whole production systems to detect low-level virus circulation, guide decisions, and move herds toward stable or negative status.
The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
The results of this study show the efficacy of mass herd vaccination to stabilize the sow herd and to production of naïve weaned pigs, allowing a better assessment of control tools of PRRSV in growing pigs.
After the evaluation of the trial the farm started to use Ingelvac® PRRS MLV in sows (mass vaccination of all breeding animals every 3 month) and pigs (vaccination at 10 days of age) as a tool to control PRRS
Vaccination did not prevent infection, but reduced the impact of clinical disease and prevented hyperpyrexia associated mortality.
Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant reproductive losses inthe sow herd and respiratory disease in growing pigs. The virus belongs to the family Arteriviridae and there are two major genotypes. Type 1 is represented by Lelystad virus, the European prototype virus,and Type 2 is represented by the North American prototype virus, VR-2332. Depending on husbandry, immune status of the herd, and virulence of the isolate, the severity of disease and magnitude of economic loss can be variable. Vaccine use is not always successful indicating a lack of cross-protection between vaccine strains and circulating wild-type viruses. To date, there is no clear method to demonstrate if a vaccine confers protection against a specific isolate except for empirical animal studies.